In Vitro Sensitization Testing using the GARD™ Platform

MB Research Labs - SenzaGen Collaboration

MB Research & SenzaGen Collaboration - GARD™ Sensitization Testing Platform

SENZAGEN and MB Research Labs Logo

MB Research Labs is honored to work with SenzaGen to expand our testing portfolio and include the GARD™ test platform for in vitro sensitization testing.

Genomic Allergen Rapid Detection – GARD™ – is an in vitro platform for safety assessment of chemicals. The first GARD™ application, GARDskin, is a peer-reviewed assay that is considered for ECVAM validation and prioritized by the Cosmetics Europe Skin Tolerance Task Force. GARDskin is intended to replace the use of animal experiments in safety assessment of products and product constituents from the cosmetic, chemical and pharmaceutical industry.

In short, cell-cultures with in vivo like features are used as a model for the human immune system, which reacts differentially to allergenic stimulations compared to harmless substances. Following cellular stimulation, the stimulatory agent can be classified according to its hazardous properties by evaluating a set of reporter probes, so-called genomic biomarkers.

How GARD™ Works?

GARD Genomic Sensitization Testing. in vitro Genetic Testing to Determine the Allergenicity of the Chemicals.

The GARD™ method mimics the immune system by predicting the ability of chemical compounds to induce skin sensitization by using a genomic biomarker signature to predict the sensitizing ability of chemical compounds. These biomarkers represent the various activated mechanisms in dendritic cells in response to test substances.

The GARD™ platform is based on gene expression analysis of stimulated in vitro models of Dendritic cells. By mimicing the initial events of the immune system in response to foreign molecular structures, SenzaGen builds predictive models that are simple, yet able to reflect a complex reality. Upon exposure, organs and cells in the human body react in a multitude of ways in response to chemicals, proteins or other molecular structures that are recognized as foreign by the immune system. The GARD™ platform monitors these different reactions by examining transcriptional patterns induced by various stimuli, by the use of predictive genomic biomarker signatures. By tailoring different biomarker signatures to specific biological endpoints of interest, the GARD™ platform is able to predict adverse effects induced by tested substances with the help of advanced pattern recognition technologies.

GARD™ Sensitization Test Platform


Skin sensitization testing. In Vitro allergy test for classification of skin sensitizers with outstanding accuracy. Sufficient for stand alone hazard identification.


Skin sensitization potency according to GHS/CLP. In Vitro test for CLP potency classification of skin sensitizers. Add-on to GARDskin.


Respiratory sensitization testing. In Vitro, Human dendritic-like cell line. Genomic biomarker signature monitoring innate immune function, dendritic cell activation and Th2 polarisation.

Toxicology Testing Specialists

MB Research has been a leader in the use and development of In Vitro and Alternative Toxicology Methods for Cosmetic, Consumer Product, Agrochemical and Industrial Chemical Safety Assessment since the late 1980s.

Our experienced team of toxicologists can assist you with biocompatibility and pharmaceutical efficacy study designs and safety assessments for program development and regulatory submissions.
45yrs Experience in Toxicology Testing